BeiGene and CLL Society: A Partnership for Personalized Hematology Care

In the realm of personalized medicine, a notable partnership has emerged in the world of hematology. BeiGene, a global oncology company, and CLL Society, the leading authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients, have joined forces during the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. The alliance aims to advance the Test Before Treat™ campaign, emphasizing the critical importance of biomarker testing before initial treatment and retesting at each subsequent stage for CLL/SLL patients.

The collaboration between BeiGene and CLL Society is a strategic move that aligns with both organizations' commitment to improving patient outcomes. By partnering, they aim to empower patients and healthcare providers with crucial information for personalized treatment decisions. The Test Before Treat campaign highlights the significance of biomarker testing, which can help identify high-risk molecular features, such as del(17p) and TP53 mutations, present in approximately 50% of CLL/SLL patients. These features may limit the effectiveness of certain treatments and increase the likelihood of disease progression if not addressed correctly.



The partnership also underscores the shift towards targeted therapies over chemotherapy, as recommended by the National Comprehensive Cancer Network® (NCCN®) guidelines. Covalent Bruton’s tyrosine kinase (BTK) inhibitors, for instance, are preferred treatments for people with CLL/SLL, as they work to shut down the BTK protein, preventing cancerous B cells from growing and spreading. By highlighting the importance of biomarker testing, the Test Before Treat campaign encourages a more informed approach to treatment decisions, potentially leading to better patient outcomes.



This collaboration allows BeiGene to stay at the forefront of CLL/SLL treatment by aligning with the leading authority in the field, CLL Society. As treatment guidelines shift towards personalized medicine, this partnership ensures BeiGene's products remain relevant and effective. By educating healthcare providers and patients about biomarker testing, the Test Before Treat campaign helps optimize treatment selection and outcome, positioning BeiGene as a key player in the evolving hematology landscape.

In conclusion, the partnership between BeiGene and CLL Society is a significant step towards advancing personalized medicine in hematology. By promoting biomarker testing and targeted therapies, this collaboration seeks to improve patient outcomes and enhance the quality of life for individuals living with CLL/SLL. As the Test Before Treat campaign gains traction, it is poised to influence treatment decisions and shape the future of hematology care.